Optimizing dose-dense regimens for early-stage breast cancer.
Patrick G
PG
Morris
Clifford A
CA
Hudis
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D017326:Clinical Trials, Phase III as Topic / Q000706:statistics & numerical data; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D004921:Erythropoietin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008408:Mastectomy; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D011994:Recombinant Proteins; D016019:Survival Analysis
D011994:Recombinant Proteins; D004921:Erythropoietin; D015251:Epirubicin; D003520:Cyclophosphamide; D017239:Paclitaxel